Franklin Parlapiano Turner & Welch LLC Acquires 548 Shares of Johnson & Johnson (NYSE:JNJ)

Franklin Parlapiano Turner & Welch LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,439 shares of the company’s stock after purchasing an additional 548 shares during the quarter. Johnson & Johnson comprises approximately 2.0% of Franklin Parlapiano Turner & Welch LLC’s investment portfolio, making the stock its 18th biggest position. Franklin Parlapiano Turner & Welch LLC’s holdings in Johnson & Johnson were worth $7,850,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Romano Brothers AND Company boosted its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Romano Brothers AND Company now owns 36,597 shares of the company’s stock worth $5,931,000 after acquiring an additional 136 shares during the period. Patrick M Sweeney & Associates Inc. boosted its stake in Johnson & Johnson by 1.2% in the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 8,987 shares of the company’s stock valued at $1,456,000 after purchasing an additional 103 shares during the period. International Assets Investment Management LLC increased its position in Johnson & Johnson by 20,130.0% during the 3rd quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock worth $559,832,000 after buying an additional 3,437,397 shares during the period. Heartland Bank & Trust Co lifted its holdings in shares of Johnson & Johnson by 2.8% during the third quarter. Heartland Bank & Trust Co now owns 9,158 shares of the company’s stock worth $1,484,000 after buying an additional 248 shares in the last quarter. Finally, McAdam LLC boosted its position in shares of Johnson & Johnson by 20.3% in the third quarter. McAdam LLC now owns 7,621 shares of the company’s stock valued at $1,235,000 after acquiring an additional 1,287 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 1.3 %

JNJ stock opened at $163.67 on Friday. The stock has a market capitalization of $393.90 billion, a P/E ratio of 10.20, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $163.29 and a 200-day moving average price of $154.92. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the previous year, the firm posted $2.66 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.03%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.